Dublin, Jan. 03, 2017 -- Research and Markets has announced the addition of the "Acne Vulgaris Forecast in 15 Major Markets 2016-2026" report to their offering.
This report provides the current prevalent population for Acne Vulgaris across 15 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Turkey, Poland, Australia, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Acne Vulgaris have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Acne Vulgaris include:
- Underlying hormone imbalance
- Puberty
- Family history
- Skin scarring
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Acne Vulgaris
10. Features of Acne Vulgaris patients
11. Predominant Features of Acne Vulgaris
12. Comorbid Conditions and Features of Acne Vulgaris
13. Scarring in Patients with Acne Vulgaris
14. Location of Acne
15. Patient-Based Offering
16. Online Pricing Data and Platforms
17. References
18. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/g2tng6/acne_vulgaris
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Dermatology


Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 



